Compare TG Therapeutics Inc (TGTX) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? TG Therapeutics Inc trades at $49.64 (market cap $7.64B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.69. The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals.
| TGTX | VTIP | |
|---|---|---|
Market Cap | $7.64B | — |
Sector | Health | — |
52-Week High | $59.06 | $50.75 |
52-Week Low | $26.94 | $49.39 |
Enterprise Value | $7.84B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
VTIP trades at $49.705, up 0.05% on the day, with a neutral technical signal overall. The ETF focuses on short-term inflation-protected securities, designed to hedge against rising costs. Recent news highlights institutional buying interest, with 55 North Private Wealth increasing its stake by 12.2% as of August 2026 (SEC filing).
The outlook for VTIP is supported by persistent inflation above the Fed's target, offering a potential hedge. Risks include interest rate uncertainty and competition from other bond ETFs. Analyst sentiment is cautiously positive, emphasizing its role in inflation-sensitive portfolios amid current economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
